{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:48:32Z","timestamp":1785757712731,"version":"3.56.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Affinity (Shanghai) Biopharmaceutical Co., Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16261-2","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T11:05:51Z","timestamp":1780052751000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety, pharmacokinetics, pharmacodynamics and antitumor activity of legubicin in patients with advanced solid tumors, including lung cancer: a phase 1 dose-escalation and expansion trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Fengjuan","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junli","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqiong","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuli","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyue","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"issue":"Suppl 4","key":"16261_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003495-199700544-00003","volume":"54","author":"GN Hortob\u00e1gyi","year":"1997","unstructured":"Hortob\u00e1gyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs. 1997;54(Suppl 4):1\u20137.","journal-title":"Drugs"},{"key":"16261_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ejphar.2017.10.043","volume":"818","author":"K Renu","year":"2018","unstructured":"Renu K, V G A, P B TP, Arunachalam S. Molecular mechanism of doxorubicin-induced cardiomyopathy - An update. Eur J Pharmacol. 2018;818:241\u201353.","journal-title":"Eur J Pharmacol"},{"key":"16261_CR3","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.3389\/fphar.2018.01262","volume":"9","author":"CG Nebigil","year":"2018","unstructured":"Nebigil CG, D\u00e9saubry L. Updates in anthracycline-mediated cardiotoxicity. Front Pharmacol. 2018;9:1262.","journal-title":"Front Pharmacol"},{"key":"16261_CR4","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1126\/science.6093249","volume":"226","author":"KM Tewey","year":"1984","unstructured":"Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science. 1984;226:466\u20138.","journal-title":"Science"},{"key":"16261_CR5","doi-asserted-by":"publisher","first-page":"853","DOI":"10.4103\/0973-1482.139267","volume":"10","author":"S Rivankar","year":"2014","unstructured":"Rivankar S. An overview of doxorubicin formulations in cancer therapy. J Cancer Res Ther. 2014;10:853\u20138.","journal-title":"J Cancer Res Ther"},{"key":"16261_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1056\/NEJM198107163050305","volume":"305","author":"RC Young","year":"1981","unstructured":"Young RC, Ozols RF, Myers CE. The anthracycline antineoplastic drugs. N Engl J Med. 1981;305:139\u201353.","journal-title":"N Engl J Med"},{"key":"16261_CR7","doi-asserted-by":"publisher","first-page":"111708","DOI":"10.1016\/j.biopha.2021.111708","volume":"139","author":"PS Rawat","year":"2021","unstructured":"Rawat PS, Jaiswal A, Khurana A, Bhatti JS, Navik U. Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother. 2021;139:111708.","journal-title":"Biomed Pharmacother"},{"key":"16261_CR8","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1039\/C9NR08558K","volume":"12","author":"Y Li","year":"2020","unstructured":"Li Y, Niu Y, Zhu J, Gao C, Xu Q, He Z, et al. Tailor-made legumain\/pH dual-responsive doxorubicin prodrug-embedded nanoparticles for efficient anticancer drug delivery and in situ monitoring of drug release. Nanoscale. 2020;12:2673\u201385.","journal-title":"Nanoscale"},{"key":"16261_CR9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10637-014-0183-5","volume":"33","author":"MM Mita","year":"2015","unstructured":"Mita MM, Natale RB, Wolin EM, Laabs B, Dinh H, Wieland S, et al. Pharmacokinetic study of aldoxorubicin in patients with solid tumors. Invest New Drugs. 2015;33:341\u20138.","journal-title":"Invest New Drugs"},{"key":"16261_CR10","doi-asserted-by":"publisher","first-page":"4858","DOI":"10.1158\/1078-0432.CCR-06-2776","volume":"13","author":"C Unger","year":"2007","unstructured":"Unger C, H\u00e4ring B, Medinger M, Drevs J, Steinbild S, Kratz F, et al. Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin. Clin Cancer Res. 2007;13:4858\u201366.","journal-title":"Clin Cancer Res"},{"key":"16261_CR11","doi-asserted-by":"publisher","first-page":"8090","DOI":"10.1074\/jbc.272.12.8090","volume":"272","author":"JM Chen","year":"1997","unstructured":"Chen JM, Dando PM, Rawlings ND, Brown MA, Young NE, Stevens RA, et al. Cloning, isolation, and characterization of mammalian legumain, an asparaginyl endopeptidase. J Biol Chem. 1997;272:8090\u20138.","journal-title":"J Biol Chem"},{"key":"16261_CR12","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.3390\/biomedicines11113080","volume":"11","author":"S Balamkundu","year":"2023","unstructured":"Balamkundu S, Liu CF. Lysosomal-cleavable peptide linkers in antibody-drug conjugates. Biomedicines. 2023;11:3080.","journal-title":"Biomedicines"},{"key":"16261_CR13","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1515\/hsz-2019-0135","volume":"400","author":"M Poreba","year":"2019","unstructured":"Poreba M. Recent advances in the development of legumain-selective chemical probes and peptide prodrugs. Biol Chem. 2019;400:1529\u201350.","journal-title":"Biol Chem"},{"key":"16261_CR14","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1021\/acsomega.3c07163","volume":"9","author":"Y Liu","year":"2023","unstructured":"Liu Y, Corrales-Guerrero S, Kuo JC, Robb R, Nagy G, Cui T, et al. Improved targeting and safety of doxorubicin through a novel albumin binding prodrug approach. ACS Omega. 2023;9:977\u201387.","journal-title":"ACS Omega"},{"key":"16261_CR15","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1158\/0008-5472.CAN-05-2591","volume":"66","author":"W Wu","year":"2006","unstructured":"Wu W, Luo Y, Sun C, Liu Y, Kuo P, Varga J, et al. Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms. Cancer Res. 2006;66:970\u201380.","journal-title":"Cancer Res"},{"key":"16261_CR16","first-page":"2957","volume":"63","author":"C Liu","year":"2003","unstructured":"Liu C, Sun C, Huang H, Janda K, Edgington T. Overexpression of legumain in tumors is significant for invasion\/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res. 2003;63:2957\u201364.","journal-title":"Cancer Res"},{"key":"16261_CR17","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/S0959-8049(99)00074-X","volume":"35","author":"K Breist\u00f8l","year":"1999","unstructured":"Breist\u00f8l K, Hendriks HR, Fodstad O. Superior therapeutic efficacy of N-L-leucyl-doxorubicin versus doxorubicin in human melanoma xenografts correlates with higher tumour concentrations of free drug. Eur J Cancer. 1999;35:1143\u20139.","journal-title":"Eur J Cancer"},{"key":"16261_CR18","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1002\/jat.4622","volume":"44","author":"Y Wang","year":"2024","unstructured":"Wang Y, Wei L, Liu Y, Liu C, Hou M, Zhou L, et al. Biodistribution and preclinical safety profile of legubicin: a novel conjugate of doxorubicin and a legumain-cleavable peptide linker. J Appl Toxicol. 2024;44:1426\u201345.","journal-title":"J Appl Toxicol"},{"key":"16261_CR19","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3390\/molecules29040775","volume":"29","author":"L Ma","year":"2024","unstructured":"Ma L, Yu Q, Zhuang M, Yang C, Liu Y, Li Y, et al. UHPLC-MS\/MS assay for quantification of legubicin, a novel doxorubicin-based legumain-activated prodrug, and its application to pharmacokinetic and tissue distribution studies. Molecules. 2024;29:775.","journal-title":"Molecules"},{"key":"16261_CR20","first-page":"1901","volume":"60","author":"C Ferraro","year":"2000","unstructured":"Ferraro C, Quemeneur L, Prigent AF, Taverne C, Revillard JP, Bonnefoy-Berard N. Anthracyclines trigger apoptosis of both G0-G1 and cycling peripheral blood lymphocytes and induce massive deletion of mature T and B cells. Cancer Res. 2000;60:1901\u20137.","journal-title":"Cancer Res"},{"key":"16261_CR21","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1080\/15569543.2021.1912099","volume":"41","author":"K Renu","year":"2021","unstructured":"Renu K, Pureti LP, Vellingiri B, Valsala Gopalakrishnan A. Toxic effects and molecular mechanism of doxorubicin on different organs \u2013 an update. Toxin Reviews. 2021;41:650\u201374.","journal-title":"Toxin Reviews"},{"key":"16261_CR22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.2042-7158.2012.01567.x","volume":"65","author":"O Tacar","year":"2013","unstructured":"Tacar O, Sriamornsak P, Dass CR. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 2013;65:157\u201370.","journal-title":"J Pharm Pharmacol"},{"key":"16261_CR23","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/cncr.29081","volume":"121","author":"SP Chawla","year":"2015","unstructured":"Chawla SP, Chua VS, Hendifar AF, Quon DV, Soman N, Sankhala KK, et al. A phase 1B\/2 study of aldoxorubicin in patients with soft tissue sarcoma. Cancer. 2015;121:570\u20139.","journal-title":"Cancer"},{"key":"16261_CR24","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2147\/DDDT.S140638","volume":"12","author":"J Gong","year":"2018","unstructured":"Gong J, Yan J, Forscher C, Hendifar A. Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas. Drug Des Devel Ther. 2018;12:777\u201386.","journal-title":"Drug Des Devel Ther"},{"key":"16261_CR25","first-page":"309","volume":"66","author":"G Curigliano","year":"2016","unstructured":"Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, et al. Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA Cancer J Clin. 2016;66:309\u201325.","journal-title":"CA Cancer J Clin"},{"key":"16261_CR26","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1177\/1078155219877931","volume":"26","author":"HS Al-Malky","year":"2020","unstructured":"Al-Malky HS, Al Harthi SE, Osman AM. Major obstacles to doxorubicin therapy: cardiotoxicity and drug resistance. J Oncol Pharm Pract. 2020;26:434\u201344.","journal-title":"J Oncol Pharm Pract"},{"key":"16261_CR27","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1200\/JCO.2015.63.1408","volume":"33","author":"AM Poveda","year":"2015","unstructured":"Poveda AM, Selle F, Hilpert F, Reuss A, Savarese A, Vergote I, et al. Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial. J Clin Oncol. 2015;33:3836\u20138.","journal-title":"J Clin Oncol"},{"key":"16261_CR28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.addr.2017.07.007","volume":"119","author":"T Ojha","year":"2017","unstructured":"Ojha T, Pathak V, Shi Y, Hennink WE, Moonen CTW, Storm G, et al. Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors. Adv Drug Deliv Rev. 2017;119:44\u201360.","journal-title":"Adv Drug Deliv Rev"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16261-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16261-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16261-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:24:32Z","timestamp":1785756272000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16261-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16261"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16261-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"12 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This trial was conducted in accordance with the Declaration of Helsinki, International Conference on Harmonisation, and Good Clinical Practice. Trial protocol was approved by the institutional review board of Shanghai East Hospital. All patients provided written informed consent before enrollment.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial was sponsored by Affinity (Shanghai) Biopharmaceutical Co., Ltd (Shanghai, China). Yuan Liu, Wenyue Jin, and Hui Sun are employees of Affinity (Shanghai) Biopharmaceutical Co., Ltd. Cheng Liu is a founder and President of Affinity (Shanghai) Biopharmaceutical Co., Ltd. All other authors declare no conflict of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"929"}}